Clinical Trial Detail

NCT ID NCT01863550
Title Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ECOG-ACRIN Cancer Research Group
Indications

multiple myeloma

Therapies

Dexamethasone

Lenalidomide

Carfilzomib

Bortezomib

Age Groups: adult

No variant requirements are available.